Advances in oral immunomodulating therapies in relapsing multiple sclerosis

  title={Advances in oral immunomodulating therapies in relapsing multiple sclerosis},
  author={T. Derfuss and M. Mehling and Athina Papadopoulou and L. Kappos},
  journal={The Lancet Neurology},
  • T. Derfuss, M. Mehling, +1 author L. Kappos
  • Published 2020
  • Medicine
  • The Lancet Neurology
  • BACKGROUND Oral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action. These distinct mechanisms of action allow better adaption of treatments according to individual… CONTINUE READING
    18 Citations

    Paper Mentions

    Ponesimod for the treatment of relapsing multiple sclerosis
    Usage trend of oral drugs for multiple sclerosis patients in Argentina.
    Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
    • PDF
    Deciphering the heterogeneity of myeloid cells during neuroinflammation in the single‐cell era
    • 1


    Oral treatment for multiple sclerosis
    • 99
    • PDF
    Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions
    • 50
    • PDF
    Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
    • 27
    • PDF
    Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    • 39